Quarterly report pursuant to sections 13 or 15(d)

Subsequent Events - Schedule of Issued Common Stock, Warrants and Options (Details)

v2.4.0.8
Subsequent Events - Schedule of Issued Common Stock, Warrants and Options (Details) (USD $)
 9 Months Ended 9 Months Ended
Dec. 31, 2013
Mar. 31, 2013
Dec. 31, 2013
Purchasers Of Common Stock Under The Subscription Agreement And The Agincourt Agreements [Member]
Dec. 31, 2013
Holdings [Member]
Dec. 31, 2013
Holders of Senior Secured Convertible Promissory Notes Previously Issued By Pharma [Member]
Dec. 31, 2013
Holders of Convertible Unsecured Promissory Notes Issued By Pharma [Member]
Dec. 31, 2013
Placement Agents And Other Persons [Member]
Dec. 31, 2013
Certain Service Providers [Member]
Dec. 31, 2013
Employees Service Providers And Other Persons [Member]
Common stock, shares issued 10,530,000 10,530,000 6,276,960 [1] 33,229,093 [1],[2] 14,446,777 [1] 3,353,437 [1]      
Issuance of warrants during the period     6,276,960 [1]   14,446,777 [1] 3,321,600 [1] 3,660,445 [1],[3] 700,000 [1],[4]  
Equity incentive options or other grants under the 2014 Plan                 27,756,821 [1]
Issuance of warrants price per share     $ 0.625   $ 0.625 $ 0.625 $ 0.625    
Warrants expiration period     5 years   5 years 5 years 5 years 3 years  
Issuance of stock under purchase agreement price less than per share               $ 1.25  
[1] Number of shares after giving effect to the Stock Dividend.
[2] Represents 30,000,000 shares of our Common Stock issued pursuant to the Purchase Agreement and 3,229,093 shares of our Common Stock issued pursuant to the Merger Agreement.
[3] Includes (a) a warrant issued to Highline Research Advisors LLC, which is owned by an affiliate of a principal of Agincourt, to purchase an aggregate of 750,000 shares of our Common Stock, at an exercise price of $0.625 per share, issued in connection with investor relations and financial consulting services provided to Holdings and Pharma and services to be provided to us after the Merger, and (b) a warrant issued to an entity that provides certain website and investment relations related services to us to purchase an aggregate of 250,000 shares of our Common Stock, at an exercise price of $0.625 per share
[4] A warrant to purchase up to 700,000 shares of our Common Stock, that provides for the purchase of: (i) until the date that is 2 years after the Closing Date of the Merger, 500,000 shares at a price based on the initial trading price of the shares of our Common Stock on February 10, 2014 but not less than $1.25 per share; (ii) until the date that is 3 years after the Closing Date of the Merger, 100,000 shares at 140% of the price per share of the initial tranche of 500,000 shares; and (iii) until the date that is 3 years after the Closing Date of the Merger, 100,000 shares at 140% of the price per share of the second tranche, all as provided in the form of such warrant which is filed as an exhibit to this Current Report on Form 8-K (the "JLS Warrant").